FindTrial
Sign In

Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours)

DRUG2 trials

Sponsors

Innoviva Specialty Therapeutics, The University of Queensland

Conditions

Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)Mycobacterium Abscessus InfectionMycobacterium Abscessus Pulmonary DiseaseNon-Tuberculous Mycobacteria Pulmonary DiseaseNon-Tuberculous Mycobacterial (NTM) Infections

Phase 1

A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection
RecruitingNCT06801223
Innoviva Specialty TherapeuticsAcinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
Start: 2026-10-30End: 2028-05-20Target: 48Updated: 2026-03-03

Phase 2

Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial
Not yet recruitingNCT07485010
The University of QueenslandMycobacterium Abscessus Infection, Mycobacterium Abscessus Pulmonary Disease, Non-Tuberculous Mycobacterial (NTM) Infections +1
Start: 2027-04-01End: 2031-07-01Target: 300Updated: 2026-03-20

Related Papers

P-444. Population Pharmacokinetics (PPK) Analysis of Sulbactam-Durlobactam (SUD) to Support Dose Selection for Evaluation in a Clinical Trial in Pediatric Patients with Acinetobacter Baumannii-Calcoaceticus Complex (ABC) Infections
Open Forum Infectious Diseases2026-01-01